Connor, Clark & Lunn Investment Management Ltd. Crispr Therapeutics Ag Transaction History

Connor, Clark & Lunn Investment Management Ltd.

$18.8 Billion
Q3 2024

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 10, 2022	BUY	$61.1 - $83.78 $2.25 Million - $3.09 Million	36,857 Added 301.83%	49,068 $3.21 Million
Q2 2022 Aug 05, 2022	SELL	$43.23 - $73.83 $912,585 - $1.56 Million	-21,110 Reduced 63.35%	12,211 $742,000
Q1 2022 May 12, 2022	BUY	$53.19 - $79.24 $1.77 Million - $2.64 Million	33,321 New	33,321 $2.09 Million
Q4 2021 Feb 10, 2022	SELL	$70.09 - $111.29 $8.16 Million - $13 Million	-116,485 Closed	0 $0
Q3 2021 Nov 12, 2021	BUY	$110.2 - $156.64 $2.13 Million - $3.03 Million	19,343 Added 19.91%	116,485 $13 Million
Q2 2021 Aug 12, 2021	BUY	$100.84 - $161.89 $9.28 Million - $14.9 Million	91,999 Added 1788.82%	97,142 $15.7 Million
Q1 2021 May 13, 2021	BUY	$110.72 - $210.04 $569,432 - $1.08 Million	5,143 New	5,143 $627,000

Others Institutions Holding CRSP

# of Institutions

489

Shares Held

57.9M

Call Options Held

1.09M

Put Options Held

1.9M

Capital International Investors Los Angeles, CA

7.93M
Shares

$321 Million
0.07% of portfolio
Cathie Wood Ark Investment Management LLC | St. Petersburg, Fl

7.5M
Shares

$304 Million
3.35% of portfolio
State Street Corp Boston, MA

2.99M
Shares

$121 Million
0.01% of portfolio
Sumitomo Mitsui Trust Holdings, Inc.

2.97M
Shares

$120 Million
0.1% of portfolio
Nikko Asset Management Americas, Inc.

2.97M
Shares

$120 Million
1.61% of portfolio

View Full List

About CRISPR Therapeutics AG

Ticker CRSP
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 78,009,296
Market Cap $3.16B
Description
CRISPR Therapeutics AG, a gene editing company, focuses on developing gene-based medicines for serious diseases using its proprietary Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) platform. Its CRISPR/Cas9 is a gene editing technology that allows for precise directed changes to genomic DNA....

More about CRSP

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Connor, Clark & Lunn Investment Management Ltd., based on Form 13F filings with the SEC.

News

Stay updated on Connor, Clark & Lunn Investment Management Ltd. with notifications on news.

Account